In Tuesday’s Wall Street session, Rocket Pharmaceuticals Inc (NASDAQ:RCKT) shares traded at $2.96, up 6.86% from the previous session.
RCKT stock price is now -52.27% away from the 50-day moving average and -75.66% away from the 200-day moving average. The market capitalization of the company currently stands at $318.90M.
With the price target maintained at $5, Evercore ISI recently Downgraded its rating from Outperform to In-line for Rocket Pharmaceuticals Inc (NASDAQ: RCKT). On May 28, 2025, Morgan Stanley Downgraded its previous ‘Overweight’ rating to ‘Equal-Weight’ on the stock keeping its target price maintained at $7, while ‘Leerink Partners’ rates the stock as ‘Market Perform’
In other news, Militello John, insider sold 357 shares of the company’s stock on May 20 ’25. The stock was sold for $2,301 at an average price of $6.45. Upon completion of the transaction, the insider now directly owns 64,027 shares in the company, valued at $0.19 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 20 ’25, Schwartz Jonathan David sold 801 shares of the business’s stock. A total of $5,163 was realized by selling the stock at an average price of $6.45. This leaves the insider owning 235,255 shares of the company worth $0.7 million. A total of 7.39% of the company’s stock is owned by insiders.
During the past 12 months, Rocket Pharmaceuticals Inc has had a low of $2.19 and a high of $26.98. As of last week, the company has a debt-to-equity ratio of 0.06, a current ratio of 9.19, and a quick ratio of 9.19.
The company reported revenue of $64.39 million for the quarter, compared to $67.38 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -4.43 percent. For the current quarter, analysts expect RCKT to generate $4.36M in revenue.
